Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation [3]

Annals of the Rheumatic Diseases

Volumn 66, Issue 1, 2007, Pages 133-134

  De Vries, M K ^a   Wolbink, G J ^b   Stapel, S O ^b   De Groot, E R ^b   Dijkmans, B A C ^a   Aarden, L A ^b   Van Der Horst Bruinsma, I E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; ANTIBODY PRODUCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; HUMANS; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845967407     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.057745     Document Type: Letter

References (5)

1. van der Heijde D, Dijkmans BAC, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safely of infliximab in patients with ankylosing spondylitis. Arthritis Rheum 2005;52:582-91.
2. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, et al. Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 2005;44:670-6.
3. Wolbink GJ, Vis M, Lems WF, Voskuyl AE, de Groot ER, Nurmohamed MT, et al. Development of anti-infliximab antibodies in relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-15.
4. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
5. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.